Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SK10
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Zhiyi Biotech Completes Phase I Trial of SK10 for Chemotherapy-Induced Diarrhea
Details : SK10, the first Bacteroides fragilis-based LBP, has potential to mitigate 5-FU-induced injury via mitochondrial apoptotic BCL2/BAX pathway, is being explored for chemotherapy-induced diarrhea.
Brand Name : SK10
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 05, 2024
Lead Product(s) : SK10
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : SK10
Therapeutic Area : Gastroenterology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Zhiyi Biotech Received Clinical Approval from U.S. FDA for SK10 in Chemotherapy-induced Diarrhea
Details : Pre-clinical studies have indicated that SK10 can reduce the toxicity of chemotherapeutic drugs towards intestinal epithelial cells, regulate the expression of apoptosis-related proteins, reduce inflammatory cytokines, and enhance mucosal barrier functio...
Brand Name : SK10
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 18, 2022
Lead Product(s) : SK10
Therapeutic Area : Gastroenterology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?